187 related articles for article (PubMed ID: 30920135)
1. Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Su M; Chang YT; Hernandez D; Jones RJ; Ghiaur G
J Cell Mol Med; 2019 Jun; 23(6):4111-4117. PubMed ID: 30920135
[TBL] [Abstract][Full Text] [Related]
2. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
[TBL] [Abstract][Full Text] [Related]
3. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
Chang YT; Hernandez D; Alonso S; Gao M; Su M; Ghiaur G; Levis MJ; Jones RJ
Blood Adv; 2019 Mar; 3(6):908-916. PubMed ID: 30898762
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
Ghiaur G; Valkenburg KC; Esteb C; Ambinder A; Imus PH; Pienta KJ; Jones RJ
Cancer; 2023 Jun; 129(11):1744-1751. PubMed ID: 36840972
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.
Macanas-Pirard P; Leisewitz A; Broekhuizen R; Cautivo K; Barriga FM; Leisewitz F; Gidi V; Riquelme E; Montecinos VP; Swett P; Besa P; Ramirez P; Ocqueteau M; Kalergis AM; Holt M; Rettig M; DiPersio JF; Nervi B
PLoS One; 2012; 7(5):e37203. PubMed ID: 22629369
[TBL] [Abstract][Full Text] [Related]
6. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
7. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
8. The bone marrow microenvironment - Home of the leukemic blasts.
Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
12. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
13. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.
Macanas-Pirard P; Broekhuizen R; González A; Oyanadel C; Ernst D; García P; Montecinos VP; Court F; Ocqueteau M; Ramirez P; Nervi B
Oncotarget; 2017 Apr; 8(14):23073-23086. PubMed ID: 28160570
[TBL] [Abstract][Full Text] [Related]
14. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
15. Ablation of Wnt signaling in bone marrow stromal cells overcomes microenvironment-mediated drug resistance in acute myeloid leukemia.
Palani HK; Ganesan S; Balasundaram N; Venkatraman A; Korula A; Abraham A; George B; Mathews V
Sci Rep; 2024 Apr; 14(1):8404. PubMed ID: 38600158
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment.
Abdul-Aziz AM; Sun Y; Hellmich C; Marlein CR; Mistry J; Forde E; Piddock RE; Shafat MS; Morfakis A; Mehta T; Di Palma F; Macaulay I; Ingham CJ; Haestier A; Collins A; Campisi J; Bowles KM; Rushworth SA
Blood; 2019 Jan; 133(5):446-456. PubMed ID: 30401703
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
Skelding KA; Barry DL; Theron DZ; Lincz LF
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
Treaba DO; Bonal DM; Chorzalska A; Castillo-Martin M; Oakes A; Pardo M; Petersen M; Schorl C; Hopkins K; Melcher D; Zhao TC; Liang O; So EY; Reagan J; Olszewski AJ; Butera J; Anthony DC; Rintels P; Quesenberry P; Dubielecka PM
Br J Haematol; 2023 Mar; 200(6):740-754. PubMed ID: 36354085
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
20. Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.
Liu J; Masurekar A; Johnson S; Chakraborty S; Griffiths J; Smith D; Alexander S; Dempsey C; Parker C; Harrison S; Li Y; Miller C; Di Y; Ghosh Z; Krishnan S; Saha V
Oncotarget; 2015 Dec; 6(40):43048-64. PubMed ID: 26474278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
